1. Introduction
===============

Since November in 2002, a highly contagious pneumonia, severe acute respiratory syndrome (SARS), has spread rapidly in Asia, North America, and Europe. A new SARS coronavirus (SARS-CoV) has been identified as the etiological agent of the disease. Its seriousness lies in rapid transmission and high fatality (around 15%). However, the origin of SARS-CoV is still unknown, and no effective drug or vaccine is available up to now.

The SARS-CoV replicase encodes two overlapping polyproteins, pp1a and pp1b, which mediate viral replication and transcription. While a special main proteinase, 3C-like proteinase, is responsible for the cleavage of polyproteins, its functional importance make it an attractive target for drug development. Fortunately, the crystal structures of SARS-CoV main proteinase has been determined,[@BIB1], [@BIB2] which adopt a serine-protease fold and is homologous to the main proteinases from human coronavirus and transmissible gastroenteritis virus.[@BIB3] The goal of this study is to find potential inhibitors and locate the ligand-binding sites in SARS-CoV main proteinase based on comparison of nonhomologous tertiary structures, hence to provide clues to rational drug design.

2. Materials and methods
========================

The atomic coordinates of SARS-CoV main proteinase were downloaded from Protein Data Bank (ID 1Q2W). NCI program[@BIB4] was used to identify noncanonical interactions. VAST (<http://www.ncbi.nlm.nih.gov/Structure/VAST/vastsearch.html>) and DALI (<http://www.ebi.ac.uk/dali/>) programs were used to find similar structure patterns and in the main proteinase structure of SARS-CoV. The structure alignment was done by CE[@BIB5] and the structural comparison was performed by LGA.[@BIB6] The constituents of the binding pocket are determined by those residues that have at least one heavy atom (other than hydrogen) with a distance less than 5 Å from a heavy atom of inhibitor, as did in Chou et al.[@BIB7] The visualization of 3D structure was generated by PROTEINEXPLORER (<http://www.proteinexplorer.org>).

3. Results and discussion
=========================

The noncanonical interactions in SARS-CoV main proteinase structures are shown in [Figure 1](#FIG1){ref-type="fig"} . There are two pairs of main chain-side chain interactions: Glu288 (donor) and Trp 207 (acceptor), Ile152 (donor) and Phe8 (acceptor). There are four pairs of side chain--side chain interactions: Arg40 (donor) and Tyr54 (acceptor), Arg298 (donor) and Phe8 (acceptor), Pro184 (donor) and Phe185 (acceptor), and Tyr126 (donor) and Phe140 (acceptor). These residues are marked as \`@\' in [Figure 2](#FIG2){ref-type="fig"} .Figure 1Noncanonical interactions in the structure of SARS-CoV main proteinase. (A) The residue pairs involved are: Arg298 and Phe 8, Glu288 and Trp207, and Ile152 and Phe8, which are colored blue. (B) The residue pairs involved include: Arg40 and Tyr54, Pro184 and Phe185, and Tyr126 and Phe140, which are colored blue. The Cys-His catalytic dyad (Cys145 and His41) are colored green.Figure 2Structure alignment between SARS-CoV main proteinase (1Q2W) and other proteases: 1L1N (Poliovirus 3c Proteinase), 1CQQ (Rhinovirus 3c Protease), 1MBM (Nsp4 Proteinase From Equine Arteritis Virus), 1DY8 (Hepatitis C Virus Ns3 Protease), 1QA7 (Hepatitis A Virus 3c Protease), and 1DF9 (Dengue Virus Ns3-Protease). The residues marked as \`b\' indicate similar beta-sheets. The bold residues indicate structurally similar patterns. The residues marked as \`@\' make noncanonical interactions. The residues marked as \`\#\' make contact with inhibitors.

Among these interactions, Phe8 accepts two N--H⋯π bonds in a sandwich fashion, one donated by a side-side chain Arg298, and one donated by a main-side chian Ile152, as existed in human rac1.[@BIB8] Taken together with another N--H⋯π interaction between Glu288 and Trp207, these noncanonical bindings connected N-terminus and C-terminus of the enzyme together, then fixed to Ile152 (domain II) and Trp207 (domain III), this makes the domain II and III not flexible due to the loop formed by above interactions in the right and a loop already existed in the left ([Fig. 1A](#FIG1){ref-type="fig"}), that is stabilizes the structure of the protease. Furthermore, we turn to examine the remaining three pairs of interactions: Arg40 and Tyr54, Pro184 and Phe185, and Tyr126 and Phe140. It can be seen from [Figure 1B](#FIG1){ref-type="fig"} that these noncanonical bindings will be able to stabilize the protein structure around the active center formed by Cys-His catalytic dyad (Cys145 and His41). On the other hand, after binding, the small helix Arg40 and His41 locate will expect to move up, the loop Phe140 and Cys145 locate and the loop Pro184 and Phe185 locate will expect to move down, hence make the active center more open for substrate binding ([Fig. 1B](#FIG1){ref-type="fig"}). These results can be used for rational design of mutagenesis experiments and analysis of conservation of interactions at functional sites. In recent years, the noncanonical interactions have been shown to be important for the stability of protein structure[@BIB9], [@BIB10], [@BIB11] and ligand recognition.[@BIB12]

The structurally similar nonhomologous virus proteins identified by VAST and DALI methods focus on 6 proteases: 1CQQ (Rhinovirus 3c Protease With Ag7088 Inhibitor), 1L1N (Poliovirus 3c Proteinase), 1MBM (Nsp4 Proteinase From Equine Arteritis Virus), 1DY8 (Hepatitis C Virus Ns3 Protease with inhibitor FKI), 1QA7 (Hepatitis A Virus 3c Protease with inhibitor NFA) and 1DF9 (Dengue Virus Ns3-Protease Complexed With Mung-Bean Bowman--Birk Inhibitor). The structure-based sequence alignment of the above six proteases with SARS-CoV main protease is shown in [Figure 2](#FIG2){ref-type="fig"}. The results demonstrate that a number of similar beta sheets (marked by b) exist. In particular, there are three similar structural patterns showing conservative residues (bold representation). The catalytical important residues are included in the first two highly conservative patterns: His-Cys or His-Ser catalytic dyads.[@BIB2], [@BIB13], [@BIB14], [@BIB15], [@BIB16], [@BIB17], [@BIB18] In the third pattern, Gly is conservative in 6 proteases except SARS-CoV main proteinase, the significance of mutation from Gly161 to Tyr161 in SARS is unclear. Anyway, the three structural patterns form the common active center of these seven enzymes, as seen in their superpositions ([Fig. 3](#FIG3){ref-type="fig"} ).Figure 3The superposition of SARS-CoV main proteinase (1Q2W, white) with other proteases: 1L1N (Poliovirus 3c Proteinase, red), 1CQQ (Rhinovirus 3c Protease, orange), 1MBM (Nsp4 Proteinase From Equine Arteritis Virus, yellow), 1DY8 (Hepatitis C Virus Ns3 Protease, blue), 1QA7 (Hepatitis A Virus 3c Protease, gray), and 1DF9 (Dengue Virus Ns3-Protease, green).

Since these nonhomologous virus proteases share the same active center, we can consider the possibility of applying the inhibitors from these enzymes to SARS-CoV main proteinase. In fact, Anand et al.[@BIB3] has indicated that the inhibitor AG7088 may be modified to make it useful for SARS therapy. Chou et al.[@BIB7] conducted the docking studies of KZ7088 (a derivative of AG7088) to the SARS-CoV main proteinase (based on a theoretical model). Here, we studied the possibility of other inhibitors in anti-SARS drug development. [Figure 4](#FIG4){ref-type="fig"} shows the structures of docking other inhibitors from HAV, HCV and Dengue virus to SARS-CoV main proteinase, the residues that make contact with these inhibitors are marked as \`\#\' in [Figure 2](#FIG2){ref-type="fig"}. Furthermore, the corresponding binding pockets are shown in [Table 1](#TBL1){ref-type="table"} . The results reveal that these inhibitors can bind to SARS-CoV main proteinase well.Figure 4The interactions between SARS-CoV main protease (1Q2W, white cartoon) with different inhibitors, binding pockets are represented by blue ball-stick. (A) FKI inhibitor from Hepatitis C Virus Ns3 Protease (yellow spacefill). (B) NFA inhibitor from Hepatitis A Virus 3c Protease (yellow spacefill). (C) Bowman--Birk inhibitor from Dengue Virus Ns3-Protease (yellow stick).Table 1Binding pockets of SARS-CoV main proteinase for different inhibitorsFKI inhibitor from HCVNFA inhibitor from HAVBowman--Birk inhibitor from Dengue virusVAL20 MET17 GLN19 PHE140THR25 VAL18 VAL20 LEU141THR26 GLN19 THR21 ASN142LEU27 VAL20 CYS22 GLY143ASN28 THR21 GLY23 SER144PRO39 THR24 THR24 CYS145ARG40 THR25 THR25 GLY146HIS41 THR26 HR26 SER147VAL42 LEU27 LEU27 TYR161CYS44 ASN28 ASN28 MET162CYS117 GLY29 PRO39 HIS163TYR118 HIS41 ARG40 HIS164ASN119 VAL42 HIS41 MET165SER139 GLN69 VAL42 GLU166PHE140 ALA116 ILE43 LEU167LEU141 CYS117 CYS44 PRO168ASN142 TYR118 MET49 THR169GLY143 ASN119 LEU50 GLY170SER144 GLY120 ASN51 VAL171CYS145 SER121 PRO52 HIS172GLY146 PRO122 ASN53 ALA173SER147 LEU141 TYR54 GLY174TYR161 ASN142 LEU57 PHE181HIS163 GLY143 VAL114 PRO184HIS164 SER144 CYS117 PHE185MET165 CYS145 TYR118 VAL186GLU166 GLY146 ASN119 ASP187LEU167 SER147 TYR126 ARG188VAL171THR135 GLN189HIS172ILE136 THR190ALA173LYS137 ALA191PHE181GLY138 GLN192ASP187SER139 ALA193ALA194

Thus, the results above suggest that there is a link of SARS-CoV to human rhinovirus, Poliovirus, Arteritis virus, HAV, HCV, and Dengue virus. The inhibitors from these viruses could be modified to make them useful for SARS therapy. In fact, Cinatl et al.[@BIB19] reported that human interferons, a medicine widely used in HCV patients, was useful for the treatment of SARS. Anyway, whether relationships between SARS-CoV and these pathogens exist or not, the present results provide a wide clue to search for anti-SARS inhibitors.
